Interim report January – March 2017
January-March 2017 in brief›› Positive top-line results from the US clinical study with Hansa Medical’s lead candidate IdeS demonstrated that treatment with IdeS completely eliminates donor specific antibodies (DSAs), enabling transplantation of all 15 reported HLA incompatible patients. The clinical results will be presented at the American Transplant Congress (ATC) in Chicago, Illinois, on 30 April, 2017. ›› A Phase II study with IdeS in the rare autoimmune kidney disease anti-GBM antibody disease (anti-GBM) has been initiated. The study is investigator initiated at several European